SCHEMBL17799712

SCHEMBL17799712

Cc1occc1C(=O)N[C@H]1CC[C@H]1c1ccc(Cl)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.49
▸ GLA P06280 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ POLB P06746 3/20 0.46
▸ TAS1R3 Q7RTX0 1/20 0.46
▸ TAS1R1 Q7RTX1 1/20 0.46
▸ TAS1R2 Q8TE23 1/20 0.46
▸ ALDH1A1 P00352 4/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ THRB P10828 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.44
▸ ESR1 P03372 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16371739 1.00 LMNA (0.49) LMNAGLAMAPK1POLBTAS1R3
SCHEMBL17799666 0.86 TAS1R3 (0.43) TAS1R3TAS1R1TAS1R2ALDH1A1SMN1; SMN2
SCHEMBL16372326 0.83 LMNA (0.53) LMNAGLAMAPK1POLBTAS1R3
SCHEMBL17799718 0.83 LMNA (0.53) LMNAGLAMAPK1POLBTAS1R3
SCHEMBL17799662 0.82 TAS1R3 (0.43) TAS1R3TAS1R1TAS1R2
SCHEMBL17799736 0.81 TAS1R3 (0.49) GLAPOLBTAS1R3TAS1R1TAS1R2
SCHEMBL17799734 0.81 DPP4 (0.40) TAS1R3TAS1R1TAS1R2ALDH1A1NPC1
SCHEMBL17799743 0.80 SLC6A12 (0.47) POLBTAS1R3TAS1R1TAS1R2ALDH1A1
SCHEMBL17799732 0.80 ALDH1A1 (0.51) LMNAGLAMAPK1POLBTAS1R3
SCHEMBL16372250 0.78 P2RX7 (0.43) TAS1R3TAS1R1TAS1R2ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50724-E1 4-membered ring carboxamides used as nematicides SYNGENTA CROP PROTECTION AG (CH) 2026-01-06 — — US disclosed
EP-3019476-B1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2018-01-17 — — EP disclosed
US-9867371-B2 4-membered ring carboxamides used as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2018-01-16 — — US disclosed
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES TUBA3C, DDT, CYCS LMNA 3548/4885GLA 3687/4885MAPK1 4526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback